Recently, patient outcome and specific oncogene mutations in LC tumors have been associated with tumor subgroups defined by positive expression of adenocarcinoma (TTF-1/Napsin A) or squamous cell carcinoma (CK5/P40) immunohistochemistry markers [5]. The gene discussed is KRT5; the disease is adenocarcinoma.